Cellectar Biosciences ROA 2006-2018 | CLRB

Current and historical return on assets (ROA) values for Cellectar Biosciences (CLRB) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Cellectar Biosciences ROA for the three months ending June 30, 2018 was -156.77%.
Cellectar Biosciences Annual ROA
2017 -105.37
2016 -40.33
2015 -72.34
2014 -60.00
2013 -158.19
2012 -76.64
2011 -70.39
2010 -94.96
2009 -249.37
2008 -1,122.17
2007 -176.07
2006 -69.51
2005 -53.14
Cellectar Biosciences Quarterly ROA
Q2 2018 -41.74
Q1 2018 -36.35
Q4 2017 -31.69
Q3 2017 -35.16
Q2 2017 -24.77
Q1 2017 -18.90
Q4 2016 -16.87
Q3 2016 -24.60
Q2 2016 -18.75
Q1 2016 14.80
Q4 2015 12.52
Q3 2015 -28.76
Q2 2015 -26.65
Q1 2015 -21.09
Q4 2014 -24.94
Q3 2014 2.06
Q2 2014 -35.42
Q1 2014 -36.61
Q4 2013 -57.93
Q3 2013 -13.63
Q2 2013 -17.03
Q1 2013 -24.13
Q4 2012 -18.79
Q3 2012 -19.75
Q2 2012 -18.82
Q1 2012 -27.25
Q4 2011 -18.61
Q3 2011 -27.29
Q2 2011 -30.78
Q1 2011 -87.01
Q4 2010 6.21
Q3 2010 -20.06
Q2 2010 -46.34
Q1 2010 92.40
Q4 2009 -144.01
Q3 2009 -45.79
Q2 2009 -104.43
Q1 2009 -25.43
Q4 2008 -146.51
Q3 2008 -56.84
Q2 2008 -81.34
Q1 2008 -105.83
Q4 2007 -58.91
Q3 2007 -40.94
Q2 2007 -20.56
Q1 2007 -24.74
Q4 2006 -22.43
Q3 2006 -19.55
Q2 2006 -8.78
Q1 2006 -7.57
Q4 2005 -14.30
Q3 2005 -16.81
Q2 2005 -48.66
Q1 2005 0.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.010B $0.000B
Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $131.648B 20.18
Abbott Laboratories (ABT) United States $120.680B 25.29
Stryker (SYK) United States $64.884B 25.07
Boston Scientific (BSX) United States $52.302B 27.21
Baxter (BAX) United States $41.507B 28.25
Zimmer Biomet Holdings (ZBH) United States $26.600B 17.09
Smith & Nephew SNATS (SNN) United Kingdom $16.217B 0.00
ResMed (RMD) United States $16.192B 32.15
Canopy Growth (CGC) Canada $11.975B 0.00
Perrigo (PRGO) Ireland $10.112B 14.35
Bio-Rad Laboratories (BIO) United States $8.981B 57.67
Hill-Rom Holdings (HRC) United States $6.093B 20.66
Insulet (PODD) United States $6.053B 0.00
Haemonetics (HAE) United States $5.742B 52.40
ICU Medical (ICUI) United States $5.439B 36.86
GW Pharmaceuticals (GWPH) United Kingdom $4.724B 0.00
Neogen (NEOG) United States $4.687B 74.58
Agios Pharmaceuticals (AGIO) United States $4.290B 0.00
Hutchison China MediTech (HCM) China $3.830B 0.00
NuVasive (NUVA) United States $3.571B 33.87
National Vision Holdings (EYE) United States $3.297B 72.82
Quidel (QDEL) United States $2.670B 54.71
NxStage Medical (NXTM) United States $1.856B 0.00
Phibro Animal Health (PAHC) United States $1.754B 24.97
Cardiovascular Systems (CSII) United States $1.262B 753.60
AtriCure (ATRC) United States $1.258B 0.00
Omeros (OMER) United States $1.180B 0.00
VAREX IMAGING (VREX) United States $1.150B 18.79
Owens & Minor (OMI) United States $1.075B 11.50
PetIQ (PETQ) United States $1.059B 34.63
Eagle Pharmaceuticals (EGRX) United States $1.039B 30.67
Cerus (CERS) United States $0.988B 0.00
Surmodics (SRDX) United States $0.972B 117.42
MacroGenics (MGNX) United States $0.958B 0.00
OraSure Technologies (OSUR) United States $0.946B 61.84
TG Therapeutics (TGTX) United States $0.750B 0.00
Insys Therapeutics (INSY) United States $0.702B 0.00
LeMaitre Vascular (LMAT) United States $0.662B 31.76
Meridian Bioscience (VIVO) United States $0.642B 21.96
Lantheus Holdings (LNTH) United States $0.620B 19.29
NanoString Technologies (NSTG) United States $0.520B 0.00
Evolus (EOLS) United States $0.507B 0.00
Quanterix (QTRX) United States $0.445B 0.00
Cytosorbents (CTSO) United States $0.415B 0.00
Utah Medical Products (UTMD) United States $0.355B 22.87
Surface Oncology (SURF) United States $0.334B 0.00
BioLife Solutions (BLFS) United States $0.290B 0.00
Bovie Medical (BVX) United States $0.239B 0.00
Rockwell Medical (RMTI) United States $0.226B 0.00
Chimerix (CMRX) United States $0.188B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.167B 0.00
Fonar (FONR) United States $0.156B 7.76
Chembio Diagnostics (CEMI) United States $0.130B 0.00
Female Health (VERU) United States $0.101B 0.00
Trinity Biotech (TRIB) Ireland $0.086B 25.81
Oramed Pharmaceuticals (ORMP) Israel $0.084B 0.00
United-Guardian (UG) United States $0.076B 16.72
Neurotrope (NTRP) United States $0.070B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.059B 0.00
CAS Medical Systems (CASM) United States $0.057B 0.00
ImmuCell (ICCC) United States $0.045B 0.00
Capricor Therapeutics (CAPR) United States $0.034B 0.00
Myomo (MYO) United States $0.028B 0.00
Valeritas Holdings (VLRX) United States $0.025B 0.00
Akers Biosciences Inc (AKER) United States $0.023B 0.00
Senestech (SNES) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
NeuroMetrix (NURO) United States $0.010B 0.00